A Multi-Center, Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Surufatinib (HMPL-012), Previously Named Sulfatinib in Advanced Solid Tumors

Protocol No
HUTCHISON-2015-012-00US1
Principal Investigator
John Charlson
Phase
I
Summary
Surufatinib is a tyrosine kinase (protein) inhibitor or blocker that works to stop or slow the growth and development of blood vessels that cancer cells need to live and multiply. Other tyrosine kinase-inhibiting drugs exist to treat cancer, but many of them are not very specific to the targeted protein and, therefore, may have unwanted side effects.
Description
To evaluate the anticancer activity of surufatinib in patients with advanced soft tissue sarcomas (STS)
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: